Change in Insulin Dose and HbA1c by Geographical Region-Results from the Diabetes Unmet Need with Basal Insulin Evaluation (DUNE) Study

被引：0
|
作者：
Mauricio, Didac
Meneghini, Luigi
Orsi, Emanuela
Klimontov, Vadim
Westerbacka, Jukka
Melas-Melt, Lydie
Pilorget, Valerie
Perfetti, Riccardo
Khunti, Kamlesh
机构：
来源：
DIABETES | 2018年 / 67卷
关键词：
D O I：
10.2337/db18-1037-P
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Basal insulin and oral antidiabetic therapy (BOT)+ a single dose of insulin glulisine (BOT+) reduces HbA1c and blood glucose values in patients with type 2 diabetes
    Lankisch, Mark
    Ferlinz, Kaus
    Scherbaum, Werner A.
    DIABETES, 2007, 56 : A51 - A52
  • [22] Basal insulin and oral antidiabetic therapy (BOT)+ a single dose of insulin glulisine (BOT+) reduces HbA1c and blood glucose values in patients with type 2 diabetes
    Lankisch, M.
    FerlinZ, K.
    Scherbaum, W. A.
    DIABETOLOGIA, 2007, 50 : S404 - S405
  • [23] HbA1c, FPG, HYPOGLYCEMIA, AND BASAL INSULIN DOSE WITH INSULIN DEGLUDEC (IDeg) VS INSULIN GLARGINE 100U/ML (GLA-100): LESSONS FROM THE BEGIN PROGRAM
    Bolli, Geremia B.
    Owens, David R.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2016, 18 : A119 - A120
  • [24] Insulin detemir reduces the risk of hypoglycaemia at all levels of HbA1c compared to NPH insulin in the context of basal-bolus therapy for type 1 diabetes
    Jones, DR
    Kim, H
    Heller, S
    Clauson, P
    DIABETOLOGIA, 2005, 48 : A92 - A93
  • [25] Predictors of HbA1c reduction and hypoglycemia in type 2 diabetes mellitus individuals switching from premixed to basal insulin: an exploratory analysis of optimization study
    Yang, Wenying
    Du, Juan
    Zhang, Minlu
    Hou, Jing
    Zhang, Xia
    Cui, Nan
    CURRENT MEDICAL RESEARCH AND OPINION, 2022, 38 (11) : 1807 - 1814
  • [26] Achievement of individual HbA1c targets with self- vs physician-led titration of newly or recently initiated basal insulin in type 2 diabetes: DUNE real-world study results
    Berard, L.
    Mauricio, D.
    Khunti, K.
    Franco, D. R.
    Westerbacka, J.
    Candelas, C.
    Pilorget, V.
    Perfetti, R.
    Meneghini, L.
    DIABETOLOGIA, 2018, 61 : S405 - S405
  • [27] UK PROSPECTIVE DIABETES STUDY .2. REDUCTION IN HBA1C WITH BASAL INSULIN SUPPLEMENT, SULFONYLUREA, OR BIGUANIDE THERAPY IN MATURITY-ONSET DIABETES
    TURNER, RC
    DIABETES, 1985, 34 (08) : 793 - 798
  • [28] People with type 2 diabetes with lower HbA1c using insulin experience fewer cardiovascular events and death: results from the CREDIT study
    Freemantle, N.
    Danchin, N.
    Calvi-Gries, F.
    Dain, M. -P.
    Vincent, M.
    Home, P.
    DIABETOLOGIA, 2014, 57 : S54 - S54
  • [29] People with Type 2 Diabetes with Lower HbA1c Using Insulin Experience Fewer Cardiovascular Events and Deaths: Results from the CREDIT Study
    Freemantle, Nick
    Danchin, Nicolas
    Calvi-Gries, Francoise
    Dain, Marie-Paule
    Vincent, Maya
    Home, Philip
    DIABETES, 2014, 63 : A110 - A111
  • [30] Basal insulin peglispro is superior to insulin glargine in reducing HbA1c in insulin-naive patients with type 2 diabetes treated with oral antihyperglycaemic drugs: IMAGINE 2
    Davies, M. J.
    Russell-Jones, D.
    Selam, J. -L.
    Bailey, T. S.
    Kerenyi, Z.
    Luo, J.
    Bue-Valleskey, J.
    Ivanyi, T.
    Hartman, M. L.
    Jacobson, J. G.
    Jacober, S. J.
    DIABETOLOGIA, 2015, 58 : S19 - S20
12345